A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
A phase 1/2 trial of CRN09682 in neuroendocrine tumours, run by Crinetics Pharmaceuticals Inc., now recruiting.
Overview
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors is a phase 1/2 interventional study registered as NCT07129252 by Crinetics Pharmaceuticals Inc., with 150 participants planned, started 2025-11-26 and due to reach its primary completion in 2027-08. Interventions recorded: CRN09682.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Shares Neuroendocrine tumours and the tag pipeline.
- TrialStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
Shares Neuroendocrine tumours and the tag pipeline.
- TrialTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialStudy to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Shares Neuroendocrine tumours and the tag pipeline.
- TrialLutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE
Shares Neuroendocrine tumours and the tag pipeline.